Leadership in Gene Editing Horizon Discovery specializes in gene editing and gene modulation tools, providing significant opportunities to sell complementary products and services such as custom gene editing reagents, cell line engineering, and validation workflows to research labs and biotech firms focused on genetic research and therapy development.

Strategic Partnerships Recent collaborations with companies like Promega highlight Horizon’s openness to strategic alliances, opening avenues for joint product offerings, co-marketing efforts, and expanding market reach into areas like molecular diagnostics and therapeutic research.

Innovative Product Launches With developments such as predesigned synthetic sgRNA and Cas9 derivatives, Horizon presents ongoing opportunities for sales of cutting-edge gene editing tools, cell lines, and associated research services to academic institutions, biotech startups, and pharmaceutical companies pursuing precision medicine.

Global Footprint Headquartered in the UK with offices in the USA and Japan, Horizon has a broad geographic presence that allows for targeted international sales approaches and service expansion in high-growth biotech and pharma markets across North America, Europe, and Asia.

Financial Growth Potential Although revenue is within the $10M-$25M range, Horizon's acquisition by PerkinElmer and ongoing product innovation suggest significant growth potential, creating opportunities to upsell advanced gene editing solutions, custom services, and long-term strategic collaborations to existing and new clients.